quote:Originally posted by WineTrooper:quote:Originally posted by bfw:quote:Originally posted by WineTrooper:
For any biotech people, SGEN and NKTR are ripe for long term holds. I know a guy who works in that space and he feels strongly that SGEN and NKTR are takeout ripened and could be doubles this year or next. Both have impressive products in circulation and some income along with good pipelines.
Yeah...PNWRF continue up
I agree that both these biotechs look like doubles from here.
I’m playing in some smaller names looking for multi-baggers (with higher risk obviously).
Which small bios?
TH.to (THERF) - They have a parternship for a new HIV drug (Ibalizumab) that should be approved by the FDA shortly. I have peak earnings for them at over $2 in 2020. Note that I’ve held this one since 30 cents and am hopeful it takes on a trajectory like JAZZ.
Bti.v (BIOAF) - Riskier. They have technology to transport meds across the blood brain barrier. The company was previously mismanaged but now has a whole new management and board. They’ll need to raise capital but they’re priced like a cheap option at the moment anyway.